Blog Archives

Hope for patients with cutaneous squamous cell carcinoma (CSCC): Cemiplimab-Rwlc (Libtayo)

October 31, 2018 – The American Food and Drug Administration (FDA)  recently approved Cemiplimab-Rwlc (Libtayo) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.

Read more ›

Tags: , , , , , , ,

The weight-management drug Liraglutide (Saxenda) has just been approved by the FDA

December 23, 2014 – The U.S. Food and Drug Administration (FDA) just approved Saxenda (liraglutide [rDNA origin] injection) as a treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity.

The drug is approved for use in adults with a body mass index (BMI) of 30 or greater (obesity) or adults with a BMI of 27 or greater (overweight) who have at least one weight-related condition such as hypertension,

Read more ›

Tags: , , , , , , , , , , , ,

FDA approves Metreleptin [Myalept] to treat rare metabolic disease

March 19, 1014 – We just learned from a recent Press Release by the American Food and Drug Administration (FDA) on the approval of Metreleptin [Myalept] to treat leptin deficiency. Read the article below:

On February 24, 2014, the U.S. Food and Drug Administration approved Myalept (metreleptin for injection) as replacement therapy to treat the complications of leptin deficiency,

Read more ›

Tags: , , , , , , , , ,

FDA has approved Pertuzumab [Perjeta] in combination with Trastuzumab [Herceptin] and docetaxel chemotherapy for the treatment of people with HER2-positive metastatic breast cancer

June 11, 2012 – The American Food and Drug Administration (FDA) has approved Pertuzumab [Perjeta].  Pertuzumab [Perjeta] is approved in combination with Trastuzumab [Herceptin]  and docetaxel chemotherapy for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

Read more ›

Tags: , , , , ,

New Breast Cancer HER2 Diagnostic Tests Approved by FDA

June 12, 2012 — Two diagnostic tests to identify HER2-positive breast cancer have been approved by the US Food and Drug Administration (FDA) for use as companion diagnostics for the new targeted therapy Pertuzumab [Perjeta].
The tests — HercepTest and HER2 FISH pharmDx Kit — are both manufactured by Dako in Glostrup,

Read more ›

Tags: , , , , , ,

thasso: community

thasso: conditions

thasso post: magazine

View my Flipboard Magazine.

thasso: chat

[sac_happens]

thasso: tweets

thasso: categories

thasso: archives

Top